International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 3 , Pages 699-708 , 1 March 2009

Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03

  • Christina Tsien, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • Corresponding Author InformationReprint requests to: Christina Tsien, M.D., Department of Radiation Oncology, University of Michigan Medical Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109. Tel: (734) 936-4288; Fax: (734) 763-7370
    • ,
  • Jennifer Moughan, M.S.

      Affiliations

    • Radiation Therapy Oncology Group, Philadelphia, PA
    • ,
  • Jeff M. Michalski, M.D., M.B.A.

      Affiliations

    • Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO
    • ,
  • Mark R. Gilbert, M.D.

      Affiliations

    • Department of Neuro-Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • James Purdy, Ph.D.

      Affiliations

    • University of California-Davis Medical Center, Sacramento, CA
    • ,
  • Joseph Simpson, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO
    • ,
  • John J. Kresel, M.D., Ph.D.

      Affiliations

    • Arizona Oncology Services and Barrows Neurological Institute, Phoenix, AZ
    • ,
  • Walter J. Curran, M.D.

      Affiliations

    • Thomas Jefferson University, Philadelphia, PA
    • ,
  • Aidnag Diaz, M.D.

      Affiliations

    • University of Texas Health Science Center, San Antonio, TX
    • ,
  • Minesh P. Mehta, M.D.

      Affiliations

    • University of Wisconsin, Madison, WI

Received 7 March 2008 ,Revised 7 May 2008 ,Accepted 8 May 2008.

References 

  1. Mahley MS, Mettlin C, Natarajan N, et al. National survey of patterns of care for brain-tumor patients. J Neurosurg. 1989;71:826–836
  2. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncology Biol Phys. 1989;16:1405–1409
  3. Chan J, Lee S, Fraass B, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20:1635–1642
  4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  5. Arbuck SG, Ivy SP, Setser A, et al. The revised common toxicity criteria: Version 2.0. Available at: http://ctep.info.nih.gov. Accessed September 1, 2007.
  6. Cox JD, Stetz J, Pajak TF, et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  7. Thornton AF, Hegarty TJ, TenHaken RK, et al. Three dimensional treatment planning of astrocytomas: A dosimetry study of cerebral irradiation. Int J Radiat Oncol Biol Phys. 1991;20:1309–1315
  8. Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: Results of a phase II prospective trial. J Neurosurg. 1999;92:251–260
  9. Tanaka M, Ino Y, Nakagawa K, et al. High-dose conformal radiotherapy for supratentorial malignant glioma: A historical comparison. Lancet Oncol. 2005;6:953–960
  10. Sheline GE, Wara WM, Smith V. Therapeutic irradiation in brain injury. Int J Radiat Oncol Biol Phys. 1980;6:1215–1228
  11. Marks L, Spencer D. The influence of volume on the tolerance of the brain to radiosurgery. J Neurosurg. 1991;75:177–180
  12. Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys. 2006;65:1075–1086
  13. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–821
  14. Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: Initial report of Radiation Therapy Oncology Group protocol (90-05). Int J Radiat Oncol Biol Phys. 1996;34:647–654
  15. Coughlin C, Scott C, Langer C, et al. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys. 2000;48:1351–1358
  16. Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group study 83-02. Cancer. 1996;77:1535–1543
  17. Lustig RA, Seiferheld W, Berkey B, et al. Imaging response in malignant glioma, RTOG 90-06. Am J Clin Oncol. 2007;30:32–37
  18. Van Rijn, Heimans J, van den Berg J, et al. Survival of human glioma cells treated with various combination of temozolomide and x-rays. Int J Radiat Oncol Biol Phys. 2000;47:779–784
  19. Chakravarti A, Erkkinnen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma multiforme: A report on underlying mechanisms. Clin Cancer Res. 2007;12:4738–4746
  20. Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: An update and review of the literature. Acta Neuropathol. 2006;111:197–212
  21. MacDonald SM, Ahmad S, Kachris S, et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: A dosimetric comparison. J Appl Clin Med Phys. 2007;8:47–60
  22. Nelson SJ, Graves E, Pirzkall A, et al. In vivo molecular imaging for planning radiation therapy of gliomas: An application of 1H MRSI. J Magn Reson Imaging. 2002;16:464–476
  23. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511–519
  24. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol. 2007;25:4714–4721

 Supported by National Cancer Institute grants CA21661, CA37422, and 32115, and by National Institutes of Health grant U24 CA81647 (Advanced Technology Quality Assurance Consortium).

 Conflict of interest: none.

PII: S0360-3016(08)00928-0

doi: 10.1016/j.ijrobp.2008.05.034

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 3 , Pages 699-708 , 1 March 2009

Article Tools

* Image Usage & Resolution